A London AI research lab and venture fund that uses systematic strategies to invest $100,000–$200,000 in pre-seed and seed companies across Europe and North America.
Founded —
Type Venture capital 0 No funds on record yet.
No team members on record yet.
team@apexlogos.ai · 3 hours ago
Investment-fund research reviewed 2026-10-06. Publicly identified funds, dates, amounts and fundraising status are below. Undisclosed commitments remain unknown; this is not a complete register of private SPVs or parallel entities.
Fund size and investment stages
| Item | Finding | Evidence / date | Confidence and limits |
|---|---|---|---|
| Individual venture fund size | **Unknown from primary sources.** Goldilocks AI displays **$15M**. | https://goldi.ai/intelligence/vc/rule30 ; profile says last updated 2026-09-27, accessed 2026-10-06. | Low: no fund name, vintage, close date, target-versus-closed status or underlying source. Do not enter as verified committed capital. |
| Latest-known fund / newer funds | No dated official close announcement found in the checked sources or focused searches for Rule30 fund size, $15m and million-dollar funds. | S1–S2, S6; searched/accessed 2026-10-06. | Unknown; cannot establish latest fund, AUM, fund count or whether $15M refers to target or close. |
| Check size | Official site says **$100K–$200K per investment**. | S1, undated, accessed 2026-10-06. | High for current public statement; **not fund size**. |
| Conflicting check range | Founder reporting gives **$100K–$300K**. | S2, 2025-12-19. | Discrepancy: source date/strategy changes or exceptions may explain it; unresolved. Retain source-specific ranges. |
| Stages | Explicit current **pre-seed and seed** mandate. | S1. Historical pre-seed transactions: Kiin Bio, Gyre Energy and Ralio. S3–S5, S12. | High; no supported current later-stage mandate found. |
A $500 million vehicle mentioned in reporting on Potential Sciences is the UK government's **Sovereign AI fund**, not Rule30's fund and not the investee's announced round size. [S9]
Source register
All sources accessed **2026-10-06**. “Undated” means no dependable publication date was supplied by the page. Sources directly opened unless marked search-index evidence.
| Ref | URL | Date / role |
|---|---|---|
| S1 | https://www.rule30.vc/ | Undated official mandate, checks, portfolio and identity; live extraction differed from search-index portfolio. |
| S2 | https://pathfounders.com/p/is-the-future-of-venture-capital-powered-by-ai | **2025-12-19**, Amelia Isaacs founder reporting; search-index evidence. |
| S3 | https://www.b2venture.vc/stories/virtual-scientists-and-the-future-of-drug-discovery---why-we-invested-in-kiin | **2025-06-05**, official lead-investor announcement; search-index evidence. |
| S4 | https://www.linkedin.com/posts/heartfeltvc_were-excited-to-announce-our-latest-investment-activity-7336308232757411841-e-u6 | Official co-investor post, exact date not displayed in extraction; search-index evidence; $2.2M and Rule30 participation. |
| S5 | https://www.gyreenergy.com/news | **2026-07-07**, official investee press release; search-index evidence. |
| S6 | https://goldi.ai/intelligence/vc/rule30 | Third-party profile, last updated **2026-09-27**; unverified $15M claim, search-index evidence. |
| S7 | https://www.vestbee.com/insights/articles/uk-s-biotech-startup-secures-2-2-m-to-launch-the-virtual-scientist-platform-for-drug-discovery | **2025-06-05**, reputable startup reporting; search-index evidence. |
| S8 | https://www.evolvedrobotics.ai/ | Undated official company product page. |
| S9 | https://news.sky.com/story/sovereign-ai-fund-in-talks-to-back-drug-discovery-start-up-potential-sciences-13589227 | **2026-09-18**, Mark Kleinman / Sky News reporting; search-index evidence. |
| S10 | https://granular-labs.com/ | Undated official company page; sparse extraction. |
| S11 | https://www.amplibotics.ai/ | Undated official company product/backer page. |
| S12 | https://ralio.substack.com/p/ralio-raises-25m-in-europes-largest and https://www.goodwinlaw.com/en/news-and-events/news/2026/04/announcements-technology-goodwin-advises-ralio-on-raising-2-point-5-million | **2026-04-14** investee announcement and **2026-04-17** legal adviser confirmation; search-index evidence. |
| S13 | https://www.finaldose.ai/ and https://plim.com | FinalDose official page too sparse; PLIM load error. |
| S14 | https://www.braingrid.ai/ | Undated official developer-platform page. |
| S15 | https://www.unbound.living/ | Undated official health-check page. |
| S16 | https://signal.nfx.com/ and https://signal.nfx.com/firms/rule30 | NFX discovery entry point and unverified failed candidate URL; no attributable profile found. |
Funds recorded in Adex after this review:
No independently verifiable standalone fund recorded for this entity; see the research findings above. SHOW MORE
team@apexlogos.ai · 4 hours ago
Match research 2026-10-06 / Rule30 / sha256:f32b6f67748b3671f877abc176e421c51bd50acd659d0984ec483355672b6515 / part 2 of 2
Imported completed research. Baseline Adex/Signal statements describe prior state, not independent verification. Retain cited attribution, date, currency and classification caveats.
- **Evolved Robotics** provides elder-care robotics; no neural interface or direct neurotechnology was found in its checked product description. [S8]
Coverage includes the Adex baseline, live firm portfolio, targeted brain/neural/neurotech searches and the above company sites. Private or undisclosed investments remain outside observable evidence.
## Concrete notes for a later Adex reviewer
1. Use exact firm ID `Rule30`. Preserve current public mandate and cite S1; resolve the $100K–$200K versus $100K–$300K conflict rather than silently substituting a range.
2. Leave verified fund size/AUM empty pending a named fund announcement. Treat the third-party $15M as an investigation lead, not established capital.
3. Kiin Bio's amount/stage can be reviewed against the lead's **$2.2M pre-seed, 2025-06-05** statement. Secondary databases sometimes call it seed, give May 2025, or show converted £1.6M/€1.9M values; prefer primary evidence and distinguish conversions from separate rounds.
4. Review Gyre Energy's **2026-07-07 pre-seed** and Rule30 participation; separate investment from grants before setting an equity amount.
5. Resolve Lattice identity against **latticepay.io** before associating any HR software records. Reconcile current portfolio names versus the September baseline; live entries include Amplibotics AI, Minimal and PLIM, while DEVANTHRO was not visible. Do not remove historical investments solely due to a portfolio omission.
6. Investigate dates/rounds for robotics, semiconductor and molecular-AI claims. Do not infer lead status or a firm-specific check from company total amounts. No neurotech label should be added from the present evidence.
## Source register
All sources accessed **2026-10-06**. “Undated” means no dependable publication date was supplied by the page. Sources directly opened unless marked search-index evidence.
| Ref | URL | Date / role |
|---|---|---|
| S1 | https://www.rule30.vc/ | Undated official mandate, checks, portfolio and identity; live extraction differed from search-index portfolio. |
| S2 | https://pathfounders.com/p/is-the-future-of-venture-capital-powered-by-ai | **2025-12-19**, Amelia Isaacs founder reporting; search-index evidence. |
| S3 | https://www.b2venture.vc/stories/virtual-scientists-and-the-future-of-drug-discovery---why-we-invested-in-kiin | **2025-06-05**, official lead-investor announcement; search-index evidence. |
| S4 | https://www.linkedin.com/posts/heartfeltvc_were-excited-to-announce-our-latest-investment-activity-7336308232757411841-e-u6 | Official co-investor post, exact date not displayed in extraction; search-index evidence; $2.2M and Rule30 participation. |
| S5 | https://www.gyreenergy.com/news | **2026-07-07**, official investee press release; search-index evidence. |
| S6 | https://goldi.ai/intelligence/vc/rule30 | Third-party profile, last updated **2026-09-27**; unverified $15M claim, search-index evidence. |
| S7 | https://www.vestbee.com/insights/articles/uk-s-biotech-startup-secures-2-2-m-to-launch-the-virtual-scientist-platform-for-drug-discovery | **2025-06-05**, reputable startup reporting; search-index evidence. |
| S8 | https://www.evolvedrobotics.ai/ | Undated official company product page. |
| S9 | https://news.sky.com/story/sovereign-ai-fund-in-talks-to-back-drug-discovery-start-up-potential-sciences-13589227 | **2026-09-18**, Mark Kleinman / Sky News reporting; search-index evidence. |
| S10 | https://granular-labs.com/ | Undated official company page; sparse extraction. |
| S11 | https://www.amplibotics.ai/ | Undated official company product/backer page. |
| S12 | https://ralio.substack.com/p/ralio-raises-25m-in-europes-largest and https://www.goodwinlaw.com/en/news-and-events/news/2026/04/announcements-technology-goodwin-advises-ralio-on-raising-2-point-5-million | **2026-04-14** investee announcement and **2026-04-17** legal adviser confirmation; search-index evidence. |
| S13 | https://www.finaldose.ai/ and https://plim.com | FinalDose official page too sparse; PLIM load error. |
| S14 | https://www.braingrid.ai/ | Undated official developer-platform page. |
| S15 | https://www.unbound.living/ | Undated official health-check page. |
| S16 | https://signal.nfx.com/ and https://signal.nfx.com/firms/rule30 | NFX discovery entry point and unverified failed candidate URL; no attributable profile found. | SHOW MORE
team@apexlogos.ai · 4 hours ago
Match research 2026-10-06 / Rule30 / sha256:f32b6f67748b3671f877abc176e421c51bd50acd659d0984ec483355672b6515 / part 1 of 2
Imported completed research. Baseline Adex/Signal statements describe prior state, not independent verification. Retain cited attribution, date, currency and classification caveats.
# Rule30 — research handoff
- **Exact Adex ID:** `Rule30`
- **Canonical Adex URL:** https://adex.page/firms/Rule30
- **Research date / source access date:** 2026-10-06
- **Status:** research completed with explicit gaps; no Adex changes made.
Rule30 is a London venture investor and AI research lab using an algorithmic investment process. Its official mandate is pre-seed and seed in Europe and North America. Verified examples include **Kiin Bio** and **Gyre Energy**; its portfolio also supports robotics and semiconductor exposure. A public **$15 million fund-size claim remains unverified**. **No verified neurotech investment found in the sources checked.** [S1–S6]
## Adex MCP starting evidence
The exact-ID record came from read-only Adex MCP `Search`, endpoint `http://localhost:3000/mcp` , arguments `{"_type":"Org","term":"Rule30","labels":["Match"]}`, retrieved **2026-10-06T19:28:52.534Z**. The preserved raw record is `data/research/_sources/Rule30.adex.json`.
Adex describes a London AI research lab and venture fund investing $100,000–$200,000 at pre-seed and seed in Europe/North America. It has no founded date, no structured check-size values and no NFX Signal URL. It contains **37 investment participations**, all using https://www.rule30.vc/ as source with prior research evidence dated **2026-09-14**; announcement dates, round amounts and individual participation amounts are absent. Relevant baseline company names include DEVANTHRO, Evolved Robotics, FINALDOSE, GRANULAR LABS, GYRE ENERGY, KIIN BIO, Potential Sciences, BRAINGRID and Unbound. These are database claims, not independent deal confirmations.
Important identity discrepancy: Adex's `LatticeHQ` participation is named “Lattice,” while the live firm portfolio links Lattice to **https://latticepay.io/** , a fintech company. Do not assume this is the well-known HR software company. [S1]
## NFX Signal starting evidence and limitations
No baseline Signal URL was present. Searches on **2026-10-06** for `site:signal.nfx.com Rule30`, `site:signal.nfx.com "Rule 30"`, and the team names **Guy Conway**, **Damian Cristian** and **Felix Winckler** did not identify an attributable firm or investor profile. Broader Conway results concerned unrelated investors. The candidate URL https://signal.nfx.com/firms/rule30 failed to load with an internal error; its existence and identity are unverified. Signal's entry point is https://signal.nfx.com/ .
**No Signal claims are used as evidence in this handoff.** This is a search/access limitation, not proof that the firm or its team has no Signal presence. The team names used for searching appear in a dated founder interview/report. [S2]
## Fund size and investment stages
| Item | Finding | Evidence / date | Confidence and limits |
|---|---|---|---|
| Individual venture fund size | **Unknown from primary sources.** Goldilocks AI displays **$15M**. | https://goldi.ai/intelligence/vc/rule30 ; profile says last updated 2026-09-27, accessed 2026-10-06. | Low: no fund name, vintage, close date, target-versus-closed status or underlying source. Do not enter as verified committed capital. |
| Latest-known fund / newer funds | No dated official close announcement found in the checked sources or focused searches for Rule30 fund size, $15m and million-dollar funds. | S1–S2, S6; searched/accessed 2026-10-06. | Unknown; cannot establish latest fund, AUM, fund count or whether $15M refers to target or close. |
| Check size | Official site says **$100K–$200K per investment**. | S1, undated, accessed 2026-10-06. | High for current public statement; **not fund size**. |
| Conflicting check range | Founder reporting gives **$100K–$300K**. | S2, 2025-12-19. | Discrepancy: source date/strategy changes or exceptions may explain it; unresolved. Retain source-specific ranges. |
| Stages | Explicit current **pre-seed and seed** mandate. | S1. Historical pre-seed transactions: Kiin Bio, Gyre Energy and Ralio. S3–S5, S12. | High; no supported current later-stage mandate found. |
A $500 million vehicle mentioned in reporting on Potential Sciences is the UK government's **Sovereign AI fund**, not Rule30's fund and not the investee's announced round size. [S9]
## Previous deep-tech investments
“Deep tech” below is a research classification based on underlying science or engineering. It is not an assertion that every AI/SaaS portfolio company qualifies. Amounts are company financing totals unless explicitly stated; **Rule30's own check is unknown in every example**.
| Company | Technology rationale and attribution | Round / date / evidence |
|---|---|---|
| **Kiin Bio** | AI virtual scientists that coordinate drug-discovery research, scientific tools, laboratory data and computational workflows. Scientific AI/techbio example; integration-heavy rather than a demonstrated novel therapeutic asset. Rule30 participation is named by co-investor HEARTFELT_ and reporting; the company is also on Rule30's portfolio. | **$2.2M pre-seed**, announced **2025-06-05**, led by b2venture. The lead's official article confirms amount/stage; HEARTFELT_'s official post identifies Rule30; Vestbee corroborates. S3–S4, S7. |
| **Gyre Energy** | AI-controlled industrial cooling plus **thermal energy storage**; a physical energy-system investment. Investee's own release explicitly names Rule30. | **Pre-seed**, announced **2026-07-07**, led by Speedinvest with Rule30 and Plug and Play. Company says **over $1.3M in investment and grant funding**; equity-only amount is not isolated. Do not enter the entire figure as an equity round without clarification. S5. |
| **Evolved Robotics** | Autonomous delivery/housekeeping robots and planned mobility assistance for elder care; physical robotics and sensor engineering. Investor attribution comes from Rule30's portfolio; company site verifies product, not the financing. | Round, amount and investment date **missing**. S1, S8. |
| **Granular Labs** | Rule30 labels it semiconductors, supporting a deep-tech candidate classification. The company homepage extraction supplied only its name, Austin location and hiring link; specific chip architecture and engineering claims are **unverified**. No independent round announcement located. | Round, amount and date **missing**. S1, S10. |
| **Potential Sciences** | Drug/molecular discovery AI. Rule30 portfolio attribution; Sky News independently verifies drug-discovery business activity. | Rule30 transaction details **missing**. Sky's **2026-09-18** report describes a possible separate Sovereign AI investment as **in talks**, not closed. S1, S9. |
| **Amplibotics AI** | Company describes real-world manipulation data collected with robots for embodied AI. Its engineering/data collection activity supports a robotics/physical-AI classification. New candidate visible on current Rule30 portfolio, absent under that name in the baseline. | Round, amount/date **missing**; firm attribution is portfolio-only. Investee's visible backer list did not name Rule30 in the excerpt checked. S1, S11. |
**Additional baseline candidates requiring verification:** DEVANTHRO (historical Adex portfolio claim; absent from the live extracted portfolio), FINALDOSE (live portfolio name, but company homepage extraction yielded too little evidence to assess its technology), and PLIM (live robotics-category listing; linked https://plim.com failed to load). Do not invent rounds or assume PLIM and DEVANTHRO are the same entity. [S1, S13]
Ordinary payments and business software are not classified as deep tech here solely because they use AI. **Ralio** nevertheless provides strong independent evidence of Rule30's early-stage investing: its own announcement reports a **$2.5M pre-seed on 2026-04-14**, led by Sure Valley Ventures with Rule30 among participants; legal adviser Goodwin corroborates on 2026-04-17. [S12]
## Previous neurotech investments
**No verified neurotech investment found in the sources checked.** This does not establish that none exists.
- **BrainGrid** is an AI application-building/developer platform, not a brain-interface company; its name is not neurotech evidence. [S14]
- **Kiin Bio** and **Potential Sciences** are general drug-discovery/scientific-AI businesses in the checked evidence. No brain-specific device, neural recording/stimulation technology or neuroscience-focused investment was established. [S3, S9]
- **Unbound** markets health checks/biomarker and fitness assessment. Its site also mentions neuromuscular performance, neuroscience/cognition and psychometric assessment; those make it neuroscience/health-adjacent, but do not establish direct neural recording, stimulation or brain-interface technology. [S15] SHOW MORE
team@apexlogos.ai · 22 days ago
MATCH 
Alan Morgan
Andreas Goeldi
